NCT06032988 - Bifidobacterium animalis lactis + Lactiplantibacillus plantarum + Lactobacillus acidophilus + Saccharomyces boulardii & Type 2 Diabetes (T2D)

Background

Probiotic supplementation's role in treating type 2 diabetes (T2D) is a subject of debate.
Zikou et al. 2023 Nutrients 15(21): 4663

Study overview

NCT06032988 - Bifidobacterium animalis lactis + Lactiplantibacillus plantarum + Lactobacillus acidophilus + Saccharomyces boulardii & Type 2 Diabetes (T2D) is a randomized clinical treatment trial studying the effects of Bifidobacterium animalis lactis + Lactiplantibacillus plantarum + Lactobacillus acidophilus + Saccharomyces boulardii or placebo in 91 randomized adults with type 2 diabetes (T2D) in Greece.
Zikou et al. 2023 Nutrients 15(21): 4663

Primary outcome measures

Effects of probiotics supplementation on glycemic control (HbA1c)

Results

Significant reductions in HbA1c, fasting blood glucose, and total cholesterol were observed in the probiotic group compared to controls, even after adjusting for decreased adiposity. While no significant changes in gut microbiome diversity were noted, probiotics influenced several genera and metabolites related to diabetes.
Zikou et al. 2023 Nutrients 15(21): 4663

Conclusion

The probiotic was well-tolerated and positively impacted metabolic parameters and adiposity indices.
Zikou et al. 2023 Nutrients 15(21): 4663